Amgen (NASDAQ:AMGN) Stock Gets Downgrade from Wall Street Zen

12 Oct 2026, 05:18 by Mitch Edgeman · The Markets Daily

Amgen (NASDAQ:AMGN – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other analysts have also recently weighed in on AMGN. Barclays upped their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Wells Fargo & Company increased their price objective on Amgen from $400.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, September 4th. Guggenheim lifted their price objective on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a report on Monday, August 10th. Scotiabank boosted their target price on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. Finally, Cantor Fitzgerald upped their target price on shares of Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $389.71.

Get Our Latest Stock Report on AMGN

Amgen Price Performance

NASDAQ AMGN opened at $414.87 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock’s 50 day moving average is $412.94 and its two-hundred day moving average is $372.34. The company has a market capitalization of $224.29 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 2.99 and a beta of 0.41. Amgen has a 1-year low of $288.00 and a 1-year high of $447.03.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts forecast that Amgen will post 22.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Institutional Trading of Amgen

Several large investors have recently made changes to their positions in the business. MW Advisory LLC acquired a new position in Amgen in the 2nd quarter valued at approximately $1,054,000. Baird Financial Group Inc. raised its stake in shares of Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares during the last quarter. Integrated Advisors Network LLC lifted its holdings in shares of Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after purchasing an additional 6,356 shares during the period. KBC Group NV lifted its holdings in shares of Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after purchasing an additional 130,497 shares during the period. Finally, Nilsine Partners LLC acquired a new position in shares of Amgen during the second quarter worth $3,329,000. Institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

Positive Sentiment: UBS upgraded Amgen to Buy and raised its price target to $470 from $430, implying further upside from the reported $414.87 share price. The upgrade is the clearest near-term catalyst behind the stock’s strength. Benzinga analyst upgrade report
Positive Sentiment: Amgen announced a head-to-head Phase 3 trial for its monthly diabetes drug candidate against semaglutide. Success could strengthen the company’s position in the highly competitive GLP-1 market and provide a significant future growth opportunity, although clinical and commercial risks remain. Amgen monthly diabetes trial article
Positive Sentiment: Cantor Fitzgerald raised its Amgen price target to $440 from $400, signaling improved expectations despite maintaining a Hold rating. Cantor Fitzgerald price target report

Amgen Company Profile

(Get Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.